Loading clinical trials...
Loading clinical trials...
Double Blind, Randomized, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy of ISIS 449884 Administered Once Weekly for 26 Weeks in Patients With Type 2 Diabetes Being Treated With Metformin
The purpose of this study is to evaluate the efficacy, safety, and tolerability of ISIS-GCGRRx in combination with metformin versus placebo
Age
18 - 75 years
Sex
ALL
Healthy Volunteers
No
Ionis Investigational Site
Greenbrae, California, United States
Ionis Investigational Site
Huntington Park, California, United States
Ionis Investigational Site
La Mesa, California, United States
Ionis Investigational Site
Los Angeles, California, United States
Isis Investigational Site
Spring Valley, California, United States
Ionis Investigational Site
Port Orange, Florida, United States
Ionis Investigational Site
Marietta, Georgia, United States
Ionis Investigational Site
Oxon Hill, Maryland, United States
Ionis Investigational Site
New York, New York, United States
Ionis Investigational Site
Greensboro, North Carolina, United States
Start Date
September 1, 2015
Primary Completion Date
December 15, 2016
Completion Date
May 11, 2017
Last Updated
June 25, 2018
79
ACTUAL participants
ISIS-GCGRRx- Dose Level 1
DRUG
ISIS-GCGRRx- Dose Level 2
DRUG
Placebo
DRUG
Lead Sponsor
Ionis Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06671587